Triple immunotherapy attack shows promise against Hard-to-Treat HPV cancers

NCT ID NCT04287868

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the drugs for up to a year and are followed long-term to monitor safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PDS0101 (vaccine), M7824 (immune checkpoint inhibitor), and NHS-IL12 (immune stimulant)
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced HPV-related cancers that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 51 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the cancer may still grow or spread.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.